Induction of cuproptosis via targeting mitochondrial metabolism using dPTBD with potent therapeutic activity against KRAS-driven cancer
Cancer Letters · 2026
DOI: 10.1016/j.canlet.2026.218773 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Yichen Sun und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China; State Key Lab…. Hauptthemen laut MEDLINE: Cuproptosis, Mitochondria, Proto-Oncogene Proteins p21(ras), Copper. Die Arbeit nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Cuproptosis is a type of recently reported cell death characterized by aberrant accumulation of copper ions within cells, leading to mitochondrial stress and protein aggregation. Recent studies suggest that certain cancer cells are particularly susceptible to cuproptosis-inducing agents. However, the genetic determinants of cellular sensitivity to cuproptosis and the therapeutic potential of cuproptosis inducers in cancer treatment remain unclear. Here, we report the discovery of a small molecule, N1,N1-dimethyl-N4-(4-(pyridin-2-yl)thiazol-2-yl)benzene-1,4-diamine (dPTBD), that targets KRAS-driven cancer via a tetracycline-inducible cell-based drug screening. dPTBD exhibited significant antitumor efficacy in KRAS-driven cancers both in vitro and in vivo. Mechanistic studies revealed that dPTBD acted as a copper ionophore, promoting intracellular copper accumulation particularly in the mitochondria, leading to metabolic disruption and cuproptotic cell death. Adding trace amount of copper massively enhanced the cytotoxic effect of dPTBD, resulting in an immediate mitochondrial dysfunction and cuproptosis. In preclinical models, dPTBD, either alone or combined with physiologically tolerable amount of copper, significantly suppressed tumor growth in KRAS-mutant pancreatic and colon cancer xenografts. Taken together, our study reveals that induction of cuproptosis is a new therapeutic strategy for KRAS-driven cancer and identifies dPTBD as a lead compound for future development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of…
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China; Department of Clinical Trial Management, The Affiliate…
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China; Anhui Ribobay Pharmaceutical Co., Ltd., Chuzhou, 23951…
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. Electronic address: wenshj@sysucc.org.cn.
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. Electronic address: huangpeng@sysucc.org.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Sun, Y., Song, M., Ding, W., Liu, Q., Lu, W., Luo, B., Chen, P., Yang, J., Hu, Y., Wen, S., & Huang, P. (2026). Induction of cuproptosis via targeting mitochondrial metabolism using dPTBD with potent therapeutic activity against KRAS-driven cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218773
Vancouver
Sun Y, Song M, Ding W, Liu Q, Lu W, Luo B, et al. Induction of cuproptosis via targeting mitochondrial metabolism using dPTBD with potent therapeutic activity against KRAS-driven cancer. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218773
BibTeX
@article{Sun2026,
author = {Sun, Yichen and Song, Ming and Ding, Wenwen and Liu, Qi and Lu, Wenhua and Luo, Bingling and Chen, Ping and Yang, Jing and Hu, Yumin and Wen, Shijun and Huang, Peng},
title = {Induction of cuproptosis via targeting mitochondrial metabolism using dPTBD with potent therapeutic activity against KRAS-driven cancer},
journal = {Cancer Letters},
year = {2026},
doi = {10.1016/j.canlet.2026.218773}
}
EUVIMED